The quality of reporting of phase II and III trials for new antipsychotics: a systematic review (Q38234325)

31 August 2017

title

The quality of reporting of phase II and III trials for new antipsychotics: a systematic review (English)

1 reference

31 August 2017

main subject

phase II clinical trial

0 references

author

Robin Murray

5

1 reference

31 August 2017

J Hellier

3

0 references

author name string

M X Patel

1

1 reference

31 August 2017

S Collins

2

1 reference

31 August 2017

G Bhatia

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

2 June 2014

1 reference

31 August 2017

published in

Psychological Medicine

1 reference

31 August 2017

volume

45

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

467-479

1 reference

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Effectiveness of second generation antipsychotics: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Better reporting of harms in randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

How to compare doses of different antipsychotics: a systematic review of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Statistics notes: Analysing controlled trials with baseline and follow up measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

Effectiveness of switching antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291714001214

7 January 2021

10.1017/S0033291714001214

Identifiers

DOI

1 reference

31 August 2017

1 reference